Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers
Pathobiology · 2024
DOI: 10.1159/000533912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, 2024. Verfasst von Ilias P Nikas und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, European University Cyprus, Nicosia, Cyprus, i.nikas@euc.ac.cy. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Progesterone, Receptors, Estrogen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Introduction
Immunohistochemistry (IHC) for the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) biomarkers has prognostic and therapeutic value in breast cancer. This study aimed to compare the expression of ER, PR, and HER2 between paired malignant effusions and tissue samples of breast cancer.
Methods
Our electronic archive was searched for all effusions diagnosed as breast carcinomas within a pre-defined period (January 2018–October 2021). Next, their cell blocks (CBs) were subjected to ER, PR, HER2 IHC, or in situ hybridization, in addition to EGFR IHC. The expression of hormone receptors (HRs) and HER2 was subsequently compared between tissue and effusion cytology samples derived from the same patients.
Results
Only 2/76 (2.6%) of the breast cancer patients analyzed showed a malignant effusion at their initial presentation. ER, PR, and HER2 discordance rates between paired malignant effusions and tissue samples obtained at initial diagnosis were 24.3% (17/73), 40.8% (29/71), and 9.1% (6/66), respectively. The HR–/HER2– status was found more often at effusions compared to paired tissue biopsies obtained at initial diagnosis (30/70 vs. 17/70; p < 0.001). In addition, the HR–/HER2– status was significantly associated with an earlier development of a malignant effusion, when found at initial diagnosis (p < 0.001; log-rank test), first recurrence/metastasis (either solid or effusion) (p = 0.012; log-rank test), effusion samples (p = 0.007; log-rank test), and any tumor sample obtained (p = 0.009; log-rank test). Lastly, EGFR overexpression in the HR–/HER2– effusion samples was significantly associated with a shorter post-effusion survival (p = 0.019; log-rank test).
Conclusion
Serous effusion cytology provides high-quality material for ancillary techniques, especially when CBs are prepared, reflecting cancer heterogeneity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, European University Cyprus, Nicosia, Cyprus, i.nikas@euc.ac.cy.
- Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
- Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Nikas, I. P., Lim, S., Im, S. A., Lee, K. H., Lee, D. W., Lee, H., & Ryu, H. S. (2024). Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers. Pathobiology. https://doi.org/10.1159/000533912
Vancouver
Nikas IP, Lim S, Im SA, Lee KH, Lee DW, Lee H, et al. Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers. Pathobiology. 2024. doi:10.1159/000533912
BibTeX
@article{Nikas2024,
author = {Nikas, Ilias P and Lim, Sojung and Im, Seock-Ah and Lee, Kyung-Hun and Lee, Dae-Won and Lee, Hyebin and Ryu, Han Suk},
title = {Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers},
journal = {Pathobiology},
year = {2024},
doi = {10.1159/000533912}
}
EUVIMED